![FDA approves second drug for a site-agnostic indication; larotrectinib was tested across 17 cancer types](https://cdn.cancerletter.com/media/2018/11/wheres-waldo-web1.jpg)
![FDA approves second drug for a site-agnostic indication; larotrectinib was tested across 17 cancer types](https://cdn.cancerletter.com/media/2018/11/wheres-waldo-web1.jpg)
Cover Story
Vitrakvi (larotrectinib) aims to treat a very small group of people—some say fewer than 3,000 new patients a year in the U.S. And since these patients have diseases that span multiple tumor sites, finding them isn't easy.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Clinical Roundup
Drugs & Targets
Trending Stories
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Lei Zheng named executive director of Mays Cancer Center
- Murphy, McKay, Nodora, Ballantyne, Stupack named associate directors at UCSD Moores
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence - NCI’s new chief data scientist Warren Kibbe tells us about efforts to get “AI-ready”
“All research now involves data science at some level.”